RESUMEN
Miller Fisher syndrome (MFS) is a variant of Guillain-Barré syndrome. Delayed facial palsy (DFP) is a symptom that occurs after other neurological symptoms begin to recover within four weeks from the onset of MFS. As there have been few detailed reports about DFP in MFS cases treated with additional immunotherapy, we investigated three cases of DFP in MFS treated with additional steroid therapies. The duration of facial palsy in our cases was 12-24 days. No severe adverse effects were observed. Although adverse side effects should be carefully monitored, additional steroid therapy might be a treatment option for MFS-DFP.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Parálisis Facial , Síndrome de Guillain-Barré , Síndrome de Miller Fisher , Humanos , Parálisis Facial/tratamiento farmacológico , Parálisis Facial/etiología , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Miller Fisher/complicaciones , Síndrome de Miller Fisher/tratamiento farmacológico , Síndrome de Miller Fisher/diagnóstico , Esteroides/uso terapéuticoRESUMEN
A 40-year-old male patient was diagnosed with invasive thymoma and myasthenia gravis in 2015. In 2016 and 2017, he experienced myasthenic crises, with an increase in size of invasive thymoma. In 2018, he received chemotherapy for the invasive thymoma. After 2 months, his symptoms rapidly progressed to myasthenic crisis with severe bulbar and respiratory symptoms, despite the significant effect of chemotherapy for the thymoma. High-dose corticosteroid, multiple plasma exchanges, and intravenous immunoglobulin did not improve the symptoms. Thus, eculizumab was administered, resulting in an improvement in his conditions. To our knowledge, this is the first report showing that eculizumab may improve myasthenic crisis with invasive thymoma.
